---
url: https://www.servicesaustralia.gov.au/leukaemia-acute-lymphoblastic-leukaemia
title: Leukaemia - acute lymphoblastic leukaemia - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:40:58.873Z
source: servicesaustralia.gov.au
---
# Leukaemia - acute lymphoblastic leukaemia

The PBS subsidises blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib for patients with acute lymphoblastic leukaemia.

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Treatment specifics](#a3)
-   [Authority applications](#a4)
-   [More information](#a5)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib under the _National Health Act 1953_, section 85 and section 100 for patients with acute lymphoblastic leukaemia.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=jrrab7f28xtjycras12yiccu) on the PBS website outlines the restrictions for prescribing blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib.

## Section 100 arrangements

### Blinatumomab and inotuzumab ozogamicin

These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

-   an approved private hospital
-   a public participating hospital.

These items aren’t PBS-subsidised for public hospital in-patients.

## Treatment specifics

### Dasatinib

To be eligible for first-line initial or second-line initial PBS-subsidised treatment with dasatinib, patients must be treated by a medical practitioner.

To be eligible for maintenance of first complete remission or second line continuing PBS-subsidised treatment with dasatinib, patients must be treated by either a:

-   medical practitioner
-   nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine.

### Ponatinib

To be eligible for initial PBS-subsidised treatment with ponatinib, patients must be treated by a medical practitioner.

To be eligible for continuing PBS-subsidised treatment with ponatinib, patients must be treated by either a:

-   medical practitioner
-   nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine.

## Authority applications

### Applying for initial treatment

#### Blinatumomab

Apply for initial (induction) authority approval to prescribe PBS-subsidised blinatumomab to treat acute lymphoblastic leukaemia in writing and either:

-   use [HPOS Form upload](/upload-forms-hpos?context=20)
-   mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [acute lymphoblastic leukaemia - blinatumomab - initial (induction) authority application form](/pb210?context=20)
-   relevant attachments.

#### Dasatinib

Apply for first-line initial authority approval to prescribe PBS-subsidised dasatinib as induction and consolidation therapy to treat acute lymphoblastic leukaemia in writing and either:

-   use [HPOS Form upload](/upload-forms-hpos?context=20)
-   mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [acute lymphoblastic leukaemia first line - dasatinib - initial (induction and consolidation) authority application form](/pb271?context=20)
-   relevant attachments.

Apply for second-line initial authority approval to prescribe PBS-subsidised dasatinib to treat acute lymphoblastic leukaemia in writing and either:

-   use [HPOS Form upload](/upload-forms-hpos?context=20)
-   mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [acute lymphoblastic leukaemia second line - dasatinib - initial authority application form](/pb077?context=20)
-   relevant attachments.

#### Imatinib

Applications for first-line initial authority approval to prescribe PBS-subsidised imatinib as induction and consolidation therapy to treat acute lymphoblastic leukaemia can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

#### Inotuzumab ozogamicin

Apply for initial authority approval to prescribe PBS-subsidised inotuzumab ozogamicin to treat acute lymphoblastic leukaemia in writing and either:

-   use [HPOS Form upload](/upload-forms-hpos?context=20)
-   mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions.
-   the completed [acute lymphoblastic leukaemia - inotuzumab ozogamicin initial (induction) authority application form](/pb269?context=20)
-   relevant attachments.

#### Ponatinib

Apply for initial authority approval to prescribe PBS-subsidised ponatinib to treat acute lymphoblastic leukaemia in writing and either:

-   use [HPOS Form upload](/upload-forms-hpos?context=20)
-   mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions.
-   the completed [acute lymphoblastic leukaemia - ponatinib - initial authority application form](/pb169?context=20)
-   relevant attachments.

### Applying for initial grandfather treatment

#### Blinatumomab

For patients who received non-PBS-subsidised blinatumomab treatment before 1 March 2025 for acute lymphoblastic leukaemia, apply for initial grandfather authority approval in writing and either:

-   use [HPOS Form upload](/upload-forms-hpos?context=20)
-   mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions.
-   the completed [acute lymphoblastic leukaemia - blinatumomab - initial grandfather authority application form](/pb381?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised blinatumomab, dasatinib, inotuzumab ozogamicin and ponatinib to treat acute lymphoblastic leukaemia can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

Continuing PBS-subsidised treatment with imatinib as maintenance of first complete remission is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
